A PHASE 3, MULTICENTER, PARALLEL-GROUP, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS ≥50 YEARS OF AGE

This purpose of this phase 3 multicenter, parallel-group, open-label study is to learn about the safety, tolerability, and immunogenicity of RSVpreF and HZ/su vaccine when given together in adults 50 years of age and older.

开始日期2025-04-04

申办/合作机构

Pfizer Inc.

NCT06763783

/ Enrolling by invitation临床4期

Vaccination in Patients With Inflammatory Rheumatic Diseases. The Impact of Anti-rheumatic Treatments on the Immunogenicity of Herpes-zoster Vaccine (Shingrix) and Protection Against Infection (HZ-REUMA)

The purpose of HZ-REUMA study is explore vaccine response and protection against shingles (herpes zoster, HZ) after vaccination with two doses of Shingrix in immunosuppressed patients with inflammatory rheumatic diseases (IRD) compared to immunocompetent patients with IRD (controls).
Hypothesis:
The immunological disturbance as part of the rheumatic disease in combination with different immunomodulating treatments may impair vaccine response to non-live HZ vaccine (Shingrix) and thereby lead to an insufficient protection against infection.
Primary objective (outcome)
1. The impact of modern anti-rheumatic treatments including synthetic disease modifying anti-rheumatic drugs (DMARDs) such as methotrexate and different biological treatments (anti-TNF, anti IL6r, anti-IL12/23/17, anti-CD20, anti-BlyS, anti-INFERON treatment, or targeted DMARDs (JAK-inhibitors) on antibody response elicited by two doses of subunit vaccine against herpes zoster (HZ) administrated 1-2 months apart in patients with IRD.
Secondary outcomes
2. The numbers and frequency of antigen specific CD4 2+ T cells expressing ≥2 or more activation markers (TNFalpha, INF-gama, interleukin-2 or CD40ligand)
3. Long-term immunogenicity of two doses of Shingrix in immunosuppressed patients with IRD measured 3 and 5 after vaccination
4. the tolerability of the vaccine, the impact on existing rheumatic disease, and possible association with onset of new autoimmune diseases
5. if vaccination against herpes zoster protects against infections in patients with inflammatory rheumatic diseases
Study Population Adult patients (18 years and older) with a clinically diagnosed inflammatory rheumatic disease and regularly followed at Skåne University Hospital, section for rheumatology in Lund/Malmö, Sweden are eligible for the study and will be offered vaccination free of charge. Control group comprises adult individuals with known inflammatory rheumatic disease without immunosuppressive treatment except for low dose prednisone (max 5 mg daily) .
Inclusion criteria:
* age ≥18 years (patients)
* regular follow up at Skåne University Hospital, section for rheumatology Lund/Malmö due to an inflammatory rheumatic disease (patients)
* receive active treatment with disease modifying anti-rheumatic drugs (DMARDs) such conventional synthetic (cs), biologic (b) or targeted synthetic (ts) DMARDs or patients without active immunosuppressive treatment (controls)
Exclusions criteria
* age <18 years (patients)
* pregnancy (women of childbearing potential, WOCBP, are not excluded since all patients using DMARDs are advised to use a safe and effective contraceptive method)
* allergy/intolerability of any component in the vaccine
* active infection inclusive herpes zoster (shingles)
* received Shingrix vaccine previously
* ongoing treatment with any immunosuppressive drug for the other diseases Target enrolment/sample size: 240. Study start date: December, 17 2024- June 30, 2029

开始日期2024-12-17

申办/合作机构

Region Skåne Holding AB

NCT06569823

/ Recruiting临床1/2期

A Phase 1/2 Randomized, Observer-Blinded, Active-Controlled, Dose, Escalation Multicenter Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults

This is a randomized, active-controlled, observer-blinded, dose-escalation multi-center trial of 2 doses of an investigational HZ vaccine (Z-1018) in approximately 440 healthy adults.

开始日期2024-06-17

申办/合作机构

Dynavax Technologies Corp.

100 项与重组带状疱疹 (GlaxoSmithKline) 相关的临床结果

登录后查看更多信息

100 项与重组带状疱疹 (GlaxoSmithKline) 相关的转化医学

登录后查看更多信息

100 项与重组带状疱疹 (GlaxoSmithKline) 相关的专利（医药）

登录后查看更多信息

3,584

项与重组带状疱疹 (GlaxoSmithKline) 相关的文献（医药）

2026-01-01·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

QS-21: Structural insights, immunological mechanisms, and prospects for rational design of safer vaccine adjuvants

Review

作者: Liu, Haicui ; Cheng, Shiji ; Wan, Li ; Hu, Yanmei ; Wu, Yuyang ; Wen, Feiyan

QS-21, a refined adjuvant based on saponins, is isolated from the bark of the soap-bark tree (Quillaja saponaria). It has garnered significant interest in the creation of next-generation vaccine adjuvants due to its robust ability to elicit Th1-type and Th2-type immunological responses. Despite its successful incorporation into licensed vaccines such as Shingrix® (herpes zoster) and Mosquirix® (malaria), the widespread application of QS-21 remains constrained by several limitations, including limited natural availability, chemical instability, dose-dependent toxicity, and an incompletely elucidated mechanism of action. This review provides a comprehensive overview of the natural sources, molecular structure, clinical applications, and immunological mechanisms of QS-21, based on research conducted both in vivo and in vitro. It also presents new developments in QS-21's structure-activity relationship (SAR), highlighting the possibility of creating less hazardous and more stable analogs through chemical synthesis and biosynthetic engineering. These strategies offer promising avenues for the rational design of novel adjuvants to support the development of more effective and safer vaccines.

2025-12-31·Human Vaccines & Immunotherapeutics

Herpes zoster vaccination: Primary care provider knowledge, attitudes, and practices

Article

作者: Wang, Jinyi ; Stempniewicz, Nikita ; Sweeney, Carolyn ; Davenport, Eric

Primary care providers (PCPs) play a key role in vaccine recommendations and uptake, but limited information exists about PCP knowledge, attitudes, and practices regarding herpes zoster (HZ) vaccination. Clinical trials have shown that recombinant zoster vaccine (RZV) significantly reduces the risk of developing HZ. Hence, RZV is recommended by the US Advisory Committee on Immunization Practices (ACIP) for adults aged ≥50 years and immunocompromised adults aged ≥19 years. However, RZV uptake varies across age groups, and is lower for adults aged 50-59 compared to those aged ≥60 years. Using a cross-sectional web-based survey, this study described provider knowledge of HZ risk factors, ACIP recommendations, attitudes toward HZ vaccination, and HZ vaccination practices/barriers. Among 301 licensed PCPs in the US, knowledge of HZ risk factors was high, but only 29% were fully aware of the ACIP recommendations. PCPs indicated that HZ vaccination was important for patients aged 50-59, 60-69, and ≥70 years, with importance increasing with advancing age. During a typical week, an average of 44% (standard deviation = 32%) of PCPs reported initiating a conversation about HZ vaccination among adults aged 50-59 years. Key perceived barriers to recommending HZ vaccines to adults were contraindications and insufficient time to assess risk factors, while perceived HZ vaccine administration challenges included patients' out-of-pocket costs and lack of motivation. Results suggest that PCPs may benefit from updated information about ACIP recommendations, while both patients and providers may benefit from streamlining the vaccination process and educational efforts focused on addressing perceived barriers.

2025-12-31·Human Vaccines & Immunotherapeutics

Off-label use of recombinant adjuvanted Herpes Zoster vaccine in a 10-year-old high-risk patient affected by epidermolysis bullosa: A case report

Article

作者: Tafuri, Silvio ; Stefanizzi, Pasquale ; Palmieri, Claudia ; Arbo, Anna ; Berti, Irene ; Noviello, Chiara ; Moscara, Lorenza

Epidermolysis bullosa is a rare genetic disorder characterized by skin fragility and blistering, resulting from mutations in dermal-epidermal junction structural proteins. Disease severity varies, with some cases involving extensive skin damage and complications secondary to chronic inflammation. Patients with immune-mediated dermatological conditions face a heightened risk of Herpes Zoster and Post-Herpetic Neuralgia, particularly during immunosuppressive treatments. A 10-year-old female with Recessive Dystrophic Epidermolysis Bullosa received off-label Recombinant adjuvanted Zoster Vaccine (RZV) - approved in individuals 18 years of age and older - before initiating Janus kinase inhibitor therapy, required to manage the underlying condition. Two standard RZV doses were administered on February 22 and April 29, 2024. No immediate vital sign alterations nor Adverse Events Following Immunization were documented in the first 7 days after immunization. A 6-month follow-up revealed no relevant emergent clinical events nor Herpes Zoster episodes. In conclusion, the case offers preliminary insights into RZV safety for high-risk pediatric patients. However, robust safety and efficacy studies are warranted to support the implementation of RZV for vulnerable individuals under 18 years of age.

410

项与重组带状疱疹 (GlaxoSmithKline) 相关的新闻（医药）

2025-10-13

·PRNewswire

GC Biopharma Secures CMO Rights for Shingles Vaccine from Curevo Vaccine

YONGIN, South Korea, Oct. 13, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a South Korean biopharmaceutical company, announced today that it has signed an agreement with Curevo Vaccine to secure contract manufacturing (CMO) rights for amezosvatein (development name: CRV-101), a recombinant shingles vaccine currently under clinical development. Under the terms of the agreement, GC Biopharma will be responsible for producing a portion of the commercial supply of amezosvatein for global markets. The global shingles vaccine market is currently dominated by GSK's Shingrix. Since its launch in 2018, the market has grown at an average annual rate of approximately 20%, expanding from KRW 1 trillion in 2017 to around KRW 6 trillion (USD ~4.4 billion) in 2024. Shingrix recorded over KRW 5 trillion (GBP 3.4 billion[1]) in global sales last year, capturing more than 90% of the market. Amezosvatein is an adjuvanted recombinant protein vaccine, similar in format to Shingrix, but uses a synthetic adjuvant designed to reduce local (injection-site pain) and systemic (influenza-like) reactions after vaccination to levels typical of conventional vaccines. The company believes this feature could position the product as a differentiated alternative with a superior tolerability profile. In fact, amezosvatein demonstrated non- inferior immune system activity in early Phase 2 trials compared to the leading competitor and showed favorable tolerability results. Currently, Curevo Vaccine is conducting an expanded Phase 2 study in 640 adults aged 50 and older. The company aims to complete this trial by 2026 and move directly into Phase 3, paving the way for global commercialization. The company expects that the addition of amezosvatein to the shingles vaccine landscape will offer patients and healthcare providers a valuable alternative, expanding choice in a market currently dominated by a single product. "This agreement marks a critical milestone in securing long-term growth drivers for GC Biopharma," said Huh Eun-Chul, CEO of GC Biopharma. "We will continue to expand our global vaccine business through strategic collaborations and differentiated technologies." [1] Source: GSK Q4 2024 Earnings Announcement About GC Biopharma GC Biopharma (formerly known as Green Cross Corporation) is a biopharmaceutical company headquartered in Yong-in, South Korea. The company has over half a century of experience in the development and manufacturing of plasma derivatives and vaccines, and is expanding its global presence with successful US market entry of Alyglo® (intravenous immunoglobulin G) in 2024. In line with its mission to meet the demands of future healthcare, GC Biopharma continues to drive innovation by leveraging its core R&D capabilities in engineering of proteins, mRNAs, and lipid nanoparticle (LNP) drug delivery platform to develop therapeutics for the field of rare disease as well as I&I (Immunology & Inflammation). To learn more about the company, visit This press release may contain biopharmaceuticals in forward-looking statements, which express the current beliefs and expectations of GC Biopharma's management. Such statements do not represent any guarantee by GC Biopharma or its management of future performance and involve known and unknown risks, uncertainties, and other factors. GC Biopharma undertakes no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. GC Biopharma Contacts (Media) Sohee Kim [email protected] Yelin Jun [email protected] Yoonjae Na [email protected] SOURCE GC Biopharma WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床2期疫苗临床结果引进/卖出

2025-10-13

·药时空

GSK 重组带状疱疹疫苗获批用于18岁及以上高危成人

10 月 11 日，NMPA 官网显示，GSK 的重组带状疱疹疫苗（GSK1437173A，欣安立适）新适应症获批上市，用于 18 岁及以上高危成人预防带状疱疹（受理号：JXSS2400007）。截图来源：NMPA 官网此次新适应症获批是基于 6 项临床试验的积极结果，试验对象为近期曾接受过造血细胞（干细胞）移植、肾移植，或患有血癌、实体瘤或艾滋病毒的 18 岁及以上的患者。结果显示，欣安立适在这些患者中具有良好的耐受性和免疫原性。欣安立适是一种重组亚单位佐剂疫苗，分两剂肌肉注射。该疫苗结合了抗原糖蛋白 E 和 AS01B 佐剂系统，旨在产生强而持久的免疫应答，帮助克服随着年龄增长而出现的免疫功能下降。欣安立适于 2017 年首次获 FDA 批准上市，用于预防 50 岁及以上成人的带状疱疹，2021 年进一步扩展适应症，获 FDA 批准用于预防 18 岁及以上因已知疾病或治疗导致的免疫缺陷或免疫抑制而处于带状疱疹高风险或即将处于高风险的人群。在国内，2019 年 5 月该疫苗首次获 NMPA 批准在中国上市，用于预防 50 岁及以上成人的带状疱疹。根据 GSK 披露的业绩，欣安立适表现不俗，2024 年销售额达 33.64 亿英镑（约 42.98 亿美元），是 GSK 销售额最高的单品。截图来源：企业财报值得一提的是，2023 年 10 月，GSK 和智飞生物签署独家经销和联合推广协议。根据协议，GSK 将向智飞生物独家供应欣安立适，并许可智飞生物在中国内地营销、推广、进口并经销该产品，而智飞生物 2024 年、2025 年、2026 年带状疱疹疫苗最低年度采购金额分别是 34.40 亿元、68.80 亿元、103.20 亿元。 Insight 数据库显示，目前国内共有 2 款带状疱疹疫苗获批上市，分别是感维（百克生物）和欣安立适（GSK）。除此之外，国内绿竹生物的重组带状疱疹疫苗-LZ901 研究进展最快，已处于上市申请阶段，拟用于预防 40 岁及以上成人水痘带状疱疹病毒引起的带状疱疹。瑞科生物、迈科康生物、中慧元通、华诺泰生物的重组带状疱疹疫苗也通紧随其后，已进入临床 III 期。截图来源：Insight 数据库注：本文转载自“丁香园Insight数据库”，原标题：GSK 重磅炸弹在华获批新适应症。

财报疫苗临床3期上市批准

2025-10-13

·生物制品圈

2025 老年人疫苗新进展，这 5 种病防护要更新！

摘要:咱们身边 65 岁以上的长辈越来越多了 ——2025 年数据显示，欧盟 65 岁以上人口已占 21.3%，80 岁以上的人未来 75 年还会增加 2.5 倍。但老年人的免疫系统会随年龄变弱（也就是 “免疫衰老”），普通疫苗效果打折扣，一旦感染流感、肺炎这些病，不仅容易住院，还可能留下走路没劲、记忆力下降的 “长期后遗症”，甚至增加心脏病、中风的风险。好消息是，2025 年最新研究里，老年人疫苗有了不少新突破：流感有高剂量疫苗，肺炎有 21 价新疫苗，带状疱疹疫苗保护率能到 97%，连之前没疫苗的 RSV（呼吸道合胞病毒）也有了新选择。今天就跟大家掰扯清楚，这些疫苗怎么选、怎么打，才能真的护好爸妈。一、先搞懂：为啥老年人打疫苗，比年轻人更重要？很多人觉得 “爸妈身体好，不用打疫苗”，其实正好相反 —— 老年人感染一次，后果可能比年轻人严重 10 倍。首先是 “免疫衰老” 在拖后腿：随着年龄增长，老年人的 B 细胞、T 细胞（都是免疫系统的 “战士”）活性会下降，就算打了疫苗，产生的抗体也少、消失得还快。比如普通流感疫苗，在年轻人里能防 70% 的感染，但老年人可能只能防 30%-50%。更麻烦的是，老年人常伴有高血压、糖尿病、慢阻肺这些 “共病”，一旦感染，很容易引发并发症。比如有慢阻肺的老人，得社区获得性肺炎的风险，是普通人的 20 倍以上；加拿大一项研究还发现，65 岁以上老人住过流感院后，12% 会去世，20% 会变得走路需要人扶（11% 甚至彻底失去自理能力）。更隐蔽的是 “长期后遗症”：感染不只是 “发烧几天就好” 这么简单。比如得了带状疱疹，3 个月后还疼的 “带状疱疹后神经痛（PHN）”，会让老人连穿衣服都疼；就算是普通肺炎，康复后几年内，心脏病、中风的风险也会升高 —— 有研究发现，流感确诊后第一周，心肌梗死的风险会增加 6 倍！所以对老年人来说，疫苗不只是 “防发烧”，更是在防残疾、防重病，甚至防死亡。二、这 5 种疫苗，老年人现在有 “升级版” 可选！以前老年人常打的只有流感、肺炎疫苗，现在不一样了，5 种高风险感染都有了更适合的疫苗，咱们一个个说：1. 流感疫苗：别再只打普通款，高剂量/佐剂款更管用流感每年都会变花样（“抗原漂移”），所以得年年打，但普通疫苗对老年人效果一般。现在有两种更好的选择：高剂量流感疫苗（HD-TIV）：抗原量是普通疫苗的 4 倍（每株 60μg vs 15μg），能让老年人产生更多抗体。研究显示，它比普通疫苗减少 24% 的肺炎住院、17.8% 的流感住院，法国 2021-22 年的数据还显示，它防流感住院的效果比普通疫苗好 23.3%。佐剂流感疫苗（aTIV）：加了 “佐剂”（比如 MF59）的疫苗，能唤醒更多免疫细胞。这种疫苗不仅抗体多，还能识别 “变异的流感病毒”（比如 H3N2 漂移株），防实验室确诊流感的效果比普通疫苗好 63%（调整后比值比 0.37）。另外，mRNA 流感疫苗也在试：就像新冠 mRNA 疫苗一样，它生产快，能更精准地匹配当年的流行株。比如候选疫苗 mRNA-1010，对甲型流感的抗体反应比普通疫苗强，还有厂家在研发 “流感 + 新冠” 二联疫苗，以后打一针能防两种病，省得爸妈跑两趟。2. 肺炎疫苗：最新 21 价疫苗，覆盖更全肺炎球菌是老年人肺炎、脑膜炎的 “头号凶手”，美国每年有 3 万老年人得侵袭性肺炎球菌病（IPD），2.5 万人会去世。以前常用的是 23 价多糖疫苗（PPV-23），但现在有了 “结合疫苗” 的升级版：从 PCV-13（13 价）到 PCV-15（15 价）、PCV-20（20 价），再到 2024 年美国获批、2025 年欧洲获批的PCV-21（21 价疫苗），覆盖的 “肺炎球菌血清型” 越来越多。特别是 PCV-21，比 PPV-23 多了 8 种老年人易感的血清型（看下面的表），能防更多类型的肺炎。虽然还没有直接的 “防住院” 数据，但它产生的抗体，比老疫苗更强、更持久（尤其是对免疫弱的老人）。表 1：肺炎球菌多糖疫苗（PPV）与结合疫苗（PCV）的血清型组成 3. 带状疱疹疫苗：选 “重组款”，保护率高、维持久带状疱疹是 “水痘病毒复活” 引起的，50 岁后发病率会飙升，80 岁以上老人几乎一半都会得。以前的 “减毒活疫苗（Zostavax）” 效果一般，70 岁以上老人用，保护率不到 20%，现在推荐的是 “重组带状疱疹疫苗（Shingrix）”：它加了 AS01B 佐剂，能激发更强的 T 细胞反应，50 岁以上老人用，保护率能到 97%，70 岁以上也能到 89.8%—— 几乎不会得带状疱疹。更省心的是，它保护时间长，打两针后能维持 10 年以上，就算是身体弱的 “frail 老人”，效果也不会打折扣；免疫低下的老人（比如肾移植后、得白血病的）也能打，这是老疫苗做不到的。4. 新冠疫苗：别停在 “基础针”，booster（加强针）要跟上虽然新冠死亡率下降了，但老年人还是高风险人群。现在的重点是 “及时打加强针”： 3 针疫苗后，防重症、防死亡的效果还能保持在 80% 以上，就算感染了，也不容易住 ICU。现在有针对最新变异株的 “更新款疫苗”，而且厂家在研发 “新冠 + 流感 + RSV” 三联疫苗，以后可能打一针就能防三种呼吸道病毒，对记性不好的老人很友好。5. RSV 疫苗：终于有了！保护能维持 2 年 RSV（呼吸道合胞病毒）以前被忽视了，其实它是老年人冬季肺炎的 “隐形凶手”—— 工业化国家里，50 岁以上老人每年约 150 万感染 RSV，21.4 万人住院，1.6% 会去世。2023-2024 年，三种 RSV 疫苗终于获批：有含佐剂的（如 GSK 的 Arexvy，加了 AS01E），也有不含佐剂的（如 Pfizer 的 Abrysvo），还有 mRNA 疫苗（Moderna 的 mRNA-1345）。效果都不错：防下呼吸道感染（比如肺炎）的效果在 66.7%-83.7% 之间，而且能保护 2 年 —— 不用像流感那样年年打。美国的真实世界数据也显示，打了 RSV 疫苗的老人，住院风险能降 80%。三、疫苗里加 “佐剂”，到底是在 “加什么料”？前面总提到 “佐剂疫苗”，很多人会问：“加佐剂会不会有副作用？” 其实佐剂是疫苗的 “好帮手”，专门帮老年人克服 “免疫衰老”。简单说，佐剂就是 “唤醒免疫系统的闹钟”：它能在注射部位吸引更多免疫细胞（比如 dendritic 细胞，相当于 “情报员”），让这些细胞更高效地把疫苗里的 “抗原”（相当于 “敌人照片”）传给 T 细胞、B 细胞，从而产生更多抗体、更强的免疫记忆。现在常用的佐剂有两种： MF59：一种油包水乳化剂（含角鲨烯，和皮肤里的成分类似），常用在流感疫苗里。它能促进炎症因子释放，帮 dendritic 细胞成熟，让抗体维持更久。 AS01B：用在带状疱疹疫苗里，包含 MPL（脂多糖衍生物）和 QS-21（一种植物提取物），能激发更强的 T 细胞反应 —— 这对带状疱疹特别重要，因为防带状疱疹主要靠 T 细胞。研究显示，加了佐剂的疫苗，不仅抗体多，还能让免疫反应更 “广谱”（比如防变异病毒），副作用和普通疫苗差不多，不用太担心。四、给家属的 3 个小提醒，别让疫苗 “白打” 别纠结 “要不要年年打”，按指南来：流感、新冠需要每年打（因为病毒会变异）；RSV、带状疱疹疫苗能管 2-10 年，不用年年打；肺炎疫苗打一次 PCV-21，一般不用补打（具体遵医嘱）。记好 “疫苗记录”：把爸妈打疫苗的时间、类型记在手机里，下次去医院时带给医生看 —— 比如打了 PCV-21，就不用再打 PPV-23 了，避免重复接种。别信 “身体弱不能打”：除了严重过敏，大部分老人就算有高血压、糖尿病，也能打疫苗。比如重组带状疱疹疫苗，肾移植、白血病患者都能打，反而这些人更需要保护。最后想说，对老年人来说，疫苗是性价比最高的 “健康保险”—— 花几百块打一针，能避免几万块的住院费，还能让爸妈少遭罪。2025 年这些疫苗新进展，都是为了让老年人的疫苗 “不白打、打得值”。如果爸妈还没打今年的疫苗，赶紧查下当地社区医院的接种时间，别错过了～识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观不本站。

疫苗

100 项与重组带状疱疹 (GlaxoSmithKline) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	重组带状疱疹 (GlaxoSmithKline)	J07BK03	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
疱疹后神经痛	欧盟	GlaxoSmithKline Biologicals SA	2018-03-21
疱疹后神经痛	冰岛	GlaxoSmithKline Biologicals SA	2018-03-21
疱疹后神经痛	列支敦士登	GlaxoSmithKline Biologicals SA	2018-03-21
疱疹后神经痛	挪威	GlaxoSmithKline Biologicals SA	2018-03-21
带状疱疹	加拿大	GlaxoSmithKline, Inc.	2017-10-13

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
呼吸道合胞体病毒感染	临床3期	美国	GSK Plc	2023-07-28
呼吸道合胞体病毒感染	临床3期	加拿大	GSK Plc	2023-07-28
新型冠状病毒感染	临床3期	美国	GSK Plc	2021-10-07
白喉	临床3期	美国	GSK Plc	2014-02-07
破伤风	临床3期	美国	GSK Plc	2014-02-07
百日咳	临床3期	美国	GSK Plc	2014-02-07
流感病毒感染	临床3期	美国	GSK Plc	2013-10-03
流感病毒感染	临床3期	加拿大	GSK Plc	2013-10-03
流感病毒感染	临床3期	德国	GSK Plc	2013-10-03
肿瘤	临床3期	美国	GSK Plc	2013-03-06

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06001606 (EULAR2025)	临床3期	系统性红斑狼疮	60	HZ/su vaccine	築憲鹹艱餘壓糧壓願鹹(鑰淵鹽艱鏇鏇衊遞衊顧) = 顧鬱蓋構鹽艱範襯願齋簾餘鹽蓋衊築艱築繭襯 (憲願遞醖夢簾鑰醖衊製, 460.0 ~ 1775.8)	积极	2025-06-11
EULAR2025	N/A	肌肉骨骼系统疾病	150	Recombinant zoster vaccine (RZV)	艱衊膚製艱艱鹹衊膚構(窪窪繭膚簾繭壓願壓鬱) = By then, pain at the site of injection in 97 (32.7%) patients was the most frequent AE, followed by fever (42 (14.1%)), fatigue (28 (9.4%)), musculoskeletal pain (24 (8.1%)), swelling at the injection side (19 (6.4%)) and redness at the injection side (19 (6.4%)). Infections (14 (4.7%)), worsening of the disease (11 (3.7%) or other AEs (n=23 (7.7%) were reported until M3. 艱鏇壓範蓋鹹構積構構 (遞築膚遞憲築醖廠範艱 ) 更多	积极	2025-06-11
NCT02723773 (ZOE-LTFU, Literature \| NEWS) 人工标引	临床3期	带状疱疹	7,273	Herpes Zoster Vaccine GSK1437173A	繭蓋獵築鹽夢選窪衊壓(衊觸壓蓋衊廠鹹餘獵蓋) = 鑰鏇鹽衊壓醖觸窪憲製鹹醖餘鏇構獵選廠觸餘 (範糧醖繭鬱積艱遞膚網, 73.7 ~ 84.6) 更多	积极	2025-05-12
NCT05966090 (RSV-OA=ADJ-020, CTgov)	临床3期	带状疱疹 \| 呼吸道合胞体病毒感染	530	HZ/su vaccine+RSVPreF3 OA investigational vaccine (Co-administration Group)	顧獵夢鏇範餘獵窪蓋夢(範網顧淵觸鏇鏇窪網選) = 壓製鹽構壓憲積範簾齋網衊願壓製製鹽鬱網築 (繭襯壓壓願鬱艱壓艱繭, 遞淵衊憲糧膚築顧鹽鑰 ~ 衊齋鬱蓋觸蓋願積鏇積) 更多	-	2025-04-01
				HZ/su vaccine+RSVPreF3 OA investigational vaccine (Control Group)	顧獵夢鏇範餘獵窪蓋夢(範網顧淵觸鏇鏇窪網選) = 鹹衊淵鑰積膚醖築壓廠網衊願壓製製鹽鬱網築 (繭襯壓壓願鬱艱壓艱繭, 觸衊齋鹹艱醖醖鹹築鏇 ~ 膚製齋艱製糧網鏇網繭) 更多
NCT04091451 (CTgov)	临床3期	带状疱疹	1,430	Herpes Zoster subunit (HZ/su) vaccine (GSK1437173A) (HZ/su Group)	膚簾艱餘淵淵廠願觸積 = 觸醖壓膚繭鹹膚構糧範餘獵鹹鹽鬱齋衊獵選繭 (糧選顧製餘願鬱鏇艱淵, 築獵艱齋齋選艱壓網積 ~ 鑰壓網齋鬱鬱艱鹹觸鹹) 更多	-	2025-03-30
				Placebo (Placebo Group)	膚簾艱餘淵淵廠願觸積 = 膚構鬱築夢願繭蓋鑰廠餘獵鹹鹽鬱齋衊獵選繭 (糧選顧製餘願鬱鏇艱淵, 廠簾構壓鏇糧製鏇醖齋 ~ 醖鏇願鹹鬱鬱襯憲鏇顧) 更多
NCT05219253 (Pubmed \| Vaccine)	临床3期	带状疱疹辅助	-	Adjuvanted Recombinant Zoster Vaccine (RZV)	憲鬱壓顧範廠鑰糧鏇艱(繭築獵獵壓遞艱艱蓋齋) = 繭醖鏇蓋鹹鹽夢遞醖廠範壓齋鏇製築衊憲願膚 (衊鏇簾構衊夢衊艱餘鬱, 78.4 ~ 91.3)	积极	2025-03-01
NCT03591770 (CTgov)	临床4期	溃疡性结肠炎	15	SHINGRIX (UC Patients on Tofacitinib Monotherapy)	餘餘製艱構製糧願繭壓 = 遞糧鹽糧蓋憲獵繭築醖獵選鏇淵窪窪範餘願衊 (顧鬱顧蓋餘夢觸淵夢觸, 鏇築鑰願鹹夢壓鑰膚構 ~ 窪遞簾鏇網網觸選觸顧) 更多	-	2025-02-21
				SHINGRIX (UC Patients on Anti-TNF Monotherapy)	餘餘製艱構製糧願繭壓 = 鏇糧網艱顧糧觸艱遞鹹獵選鏇淵窪窪範餘願衊 (顧鬱顧蓋餘夢觸淵夢觸, 鏇構網壓顧憲蓋積鹽簾 ~ 窪憲糧淵糧繭夢願繭觸) 更多
NCT04169009 (CTgov)	临床4期	带状疱疹	105	vOka varicella zoster virus (ZVL)+Zostavax (ZVL) (ZVL >5 Years Previously (Cohort 1))	鏇簾繭艱繭獵簾獵鑰壓(鬱糧艱餘蓋膚壓遞膚齋) = 構網積獵窪艱繭艱顧選鏇糧築醖願製窪餘齋鹹 (製顧艱鏇餘餘夢窪鏇顧, NA) 更多	-	2024-10-15
				ZVL (ZVL 6-12 Months Previously (Cohort 3))	鏇簾繭艱繭獵簾獵鑰壓(鬱糧艱餘蓋膚壓遞膚齋) = 顧壓製鏇網遞願願願淵鏇糧築醖願製窪餘齋鹹 (製顧艱鏇餘餘夢窪鏇顧, NA) 更多
NCT04869982 (CTgov)	临床4期	带状疱疹	6,138	RZV (RZV Group)	淵夢襯鏇艱夢壓鹹膚鹹 = 鑰鏇範繭憲獵遞範鏇鏇製窪構鏇襯廠廠製齋積 (獵鏇繭範膚鹹淵窪獵觸, 衊遞醖網壓鹹衊遞積遞 ~ 範範廠製遞獵餘顧鹹壓) 更多	-	2024-09-19
				Placebo (Placebo Group)	淵夢襯鏇艱夢壓鹹膚鹹 = 醖鹹顧淵構積餘糧築鑰製窪構鏇襯廠廠製齋積 (獵鏇繭範膚鹹淵窪獵觸, 獵觸衊襯願積衊製鏇窪 ~ 齋衊鑰襯壓獵鑰觸蓋齋) 更多
ESMO2024	N/A	肿瘤	-	Recombinant zoster vaccine (RZV, Shingrix®, GSK)	鏇糧積範獵觸蓋鹹壓鑰(鬱壓願構鑰憲簾窪艱鏇) = 夢鏇繭憲糧簾蓋夢襯構製選淵築製簾憲蓋醖蓋 (積簾蓋艱顧鹽構廠網壓 )	-	2024-09-15